A Single-center, Randomized, Double-blind, Placebo-Controlled, Dose Escalation, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of a Single Subcutaneous Injection of KLA480 Injection in Healthy Chinese Participants
Latest Information Update: 30 Jun 2025
At a glance
- Drugs KLA 480 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Sichuan Kelun Pharmaceutical Research Institute
Most Recent Events
- 30 Jun 2025 New trial record